(2S,3R,6S,7S,8S)-1-Benzyloxy-9-(tert-butyl-dimethyl-silanyloxy)-7-methoxymethoxy-2,6,8-trimethyl-non-4-yn-3-ol | 676254-73-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S,3R,6S,7S,8S)-1-Benzyloxy-9-(tert-butyl-dimethyl-silanyloxy)-7-methoxymethoxy-2,6,8-trimethyl-non-4-yn-3-ol
• 英文别名: (2S,3R,6S,7S,8S)-9-[tert-butyl(dimethyl)silyl]oxy-7-(methoxymethoxy)-2,6,8-trimethyl-1-phenylmethoxynon-4-yn-3-ol
• CAS: 676254-73-2
• 化学式: C₂₇H₄₆O₅Si
• 分子量: 478.745
• InChiKey: FSIZVKRECXIMBP-QOVNPHLHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.49
• 重原子数：
  33
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  57.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2S,3R,6S,7S,8S)-1-Benzyloxy-9-(tert-butyl-dimethyl-silanyloxy)-7-methoxymethoxy-2,6,8-trimethyl-non-4-yn-3-ol 在 palladium dihydroxide 氢气 、 三乙胺 作用下， 生成 ((2S,3S,4S,7S,8S)-9-Benzyloxy-3,7-bis-methoxymethoxy-2,4,8-trimethyl-nonyloxy)-tert-butyl-dimethyl-silane
  参考文献：
  名称：

  Applications of chiral allenylzinc additions and Noyori asymmetric reductions to an enantioselective synthesis of a C3–C13 precursor of the polyketide phosphatase inhibitor cytostatin

  摘要：

  A 12-step synthesis of a C3-C13 precursor of the protein phosphatase inhibitor cytostatin is described. Key stereocenters were introduced by a chiral allenylzinc addition and Noyori asymmetric-transfer hydrogenation. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2003.12.067
• 作为产物：
  描述：

  (2S,6S,7S,8S)-1-Benzyloxy-9-(tert-butyl-dimethyl-silanyloxy)-7-methoxymethoxy-2,6,8-trimethyl-non-4-yn-3-one 在 ((1R,2R)-N-p-toluenesulfonyl-1,2-diphenylethylenediamine)ruthenium chloride(I) (4-cymene) 、 p-cymene catalyst 作用下， 以 异丙醇 为溶剂， 以100%的产率得到(2S,3R,6S,7S,8S)-1-Benzyloxy-9-(tert-butyl-dimethyl-silanyloxy)-7-methoxymethoxy-2,6,8-trimethyl-non-4-yn-3-ol
  参考文献：
  名称：

  Applications of chiral allenylzinc additions and Noyori asymmetric reductions to an enantioselective synthesis of a C3–C13 precursor of the polyketide phosphatase inhibitor cytostatin

  摘要：

  A 12-step synthesis of a C3-C13 precursor of the protein phosphatase inhibitor cytostatin is described. Key stereocenters were introduced by a chiral allenylzinc addition and Noyori asymmetric-transfer hydrogenation. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2003.12.067